# Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

> **NCT04645160** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (estimated)

## Conditions studied

- Cholangiocarcinoma
- Bile Duct Neoplasm
- Biliary Tract Malignancy

## Interventions

- **DRUG:** Tivozanib

## Key facts

- **NCT ID:** NCT04645160
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645160, "Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT04645160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*